Literature DB >> 16423984

Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity.

Robbert G van der Most1, Andrew Currie, Bruce W S Robinson, Richard A Lake.   

Abstract

This review shows how tumor antigen cross-presentation is affected by the major therapeutic modalities including chemotherapy, radiotherapy, and surgery. We argue that this process could affect the way that a tumor works as its own cellular vaccine, and that it is differentially modulated by the choice of treatment.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16423984     DOI： 10.1158/0008-5472.CAN-05-2967

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  29 in total

1.  A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma.

Authors:  Daniela Peruzzi; Alessandra Gavazza; Giuseppe Mesiti; George Lubas; Elisa Scarselli; Antonella Conforti; Claus Bendtsen; Gennaro Ciliberto; Nicola La Monica; Luigi Aurisicchio
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

2.  Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens.

Authors:  Xi Zhao; Anamika Bose; Hideo Komita; Jennifer L Taylor; Mayumi Kawabe; Nina Chi; Laima Spokas; Devin B Lowe; Christina Goldbach; Sean Alber; Simon C Watkins; Lisa H Butterfield; Pawel Kalinski; John M Kirkwood; Walter J Storkus
Journal:  Mol Ther       Date:  2010-12-28       Impact factor: 11.454

3.  Combined influence of adjuvant therapy and interval after surgery on peripheral CD4(+) T lymphocytes in patients with esophageal squamous cell carcinoma.

Authors:  Yang Ling; Lieying Fan; Chunlei Dong; Jing Zhu; Yongping Liu; Yan Ni; Changtai Zhu; Changsong Zhang
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

4.  Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice.

Authors:  Xi Zhao; Anamika Bose; Hideo Komita; Jennifer L Taylor; Nina Chi; Devin B Lowe; Hideho Okada; Ying Cao; Debabrata Mukhopadhyay; Peter A Cohen; Walter J Storkus
Journal:  J Immunol       Date:  2012-01-13       Impact factor: 5.422

5.  Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.

Authors:  Zvi G Fridlender; Jing Sun; Sunil Singhal; Veena Kapoor; Guanjun Cheng; Eiji Suzuki; Steven M Albelda
Journal:  Mol Ther       Date:  2010-08-03       Impact factor: 11.454

6.  Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma.

Authors:  Alessandra Gavazza; George Lubas; Arthur Fridman; Daniela Peruzzi; Joseph A Impellizeri; Laura Luberto; Emanuele Marra; Giuseppe Roscilli; Gennaro Ciliberto; Luigi Aurisicchio
Journal:  Hum Gene Ther       Date:  2013-08       Impact factor: 5.695

7.  Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth.

Authors:  Hua Zhong; Baohui Han; Irina L Tourkova; Anna Lokshin; Alan Rosenbloom; Michael R Shurin; Galina V Shurin
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

8.  Delivery of Exogenous Antigens to Induce Cytotoxic CD8+ T Lymphocyte Responses.

Authors:  Julia Kim; Vandana Gambhir; Attiya Alatery; Sameh Basta
Journal:  J Biomed Biotechnol       Date:  2010-05-23

9.  Significant impairment in immune recovery after cancer treatment.

Authors:  Duck-Hee Kang; Michael T Weaver; Na-Jin Park; Barbara Smith; Traci McArdle; John Carpenter
Journal:  Nurs Res       Date:  2009 Mar-Apr       Impact factor: 2.381

10.  A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).

Authors:  Nicholas Butowski; Susan M Chang; Larry Junck; Lisa M DeAngelis; Lauren Abrey; Karen Fink; Tim Cloughesy; Kathleen R Lamborn; Andres M Salazar; Michael D Prados
Journal:  J Neurooncol       Date:  2008-09-17       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.